Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Tasly Gains Products As Transgene Sells Up China JV Stake

11 Jul 2018
Analysis

Ian Haydock @ScripIanHaydock ian.haydock@informa.com

Executive Summary

Transgene is divesting its Chinese joint venture to local partner Tasly, which is also acquiring selected rights to two Transgene products ahead of a planned IPO, in deal that will see the French firm net close to $50m in stock.

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

Topics

Regions
Asia Pacific

China

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

China Commercial Business Strategies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC123392

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC123392

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Tasly Gains Products As Transgene Sells Up China JV Stake

Analysis

Executive Summary

Related Content

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert